Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2023 | 405 | 2.610 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2023 | 239 | 2.460 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2021 | 61 | 1.120 |
Why?
|
| Mohs Surgery | 2 | 2021 | 52 | 0.800 |
Why?
|
| Keratosis, Actinic | 1 | 2021 | 3 | 0.730 |
Why?
|
| Melanoma | 1 | 2023 | 336 | 0.650 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2015 | 4 | 0.510 |
Why?
|
| Trichophyton | 1 | 2015 | 4 | 0.500 |
Why?
|
| Onychomycosis | 1 | 2015 | 6 | 0.500 |
Why?
|
| Foot Dermatoses | 1 | 2015 | 5 | 0.500 |
Why?
|
| Antifungal Agents | 1 | 2015 | 116 | 0.470 |
Why?
|
| Ear Neoplasms | 1 | 2014 | 6 | 0.460 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 153 | 0.400 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 196 | 0.370 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 268 | 0.300 |
Why?
|
| Eyelid Neoplasms | 1 | 2023 | 9 | 0.220 |
Why?
|
| Prognosis | 3 | 2023 | 1591 | 0.210 |
Why?
|
| Sunscreening Agents | 1 | 2023 | 21 | 0.210 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6147 | 0.210 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 127 | 0.200 |
Why?
|
| Dermatology | 1 | 2023 | 69 | 0.200 |
Why?
|
| Humans | 13 | 2023 | 60081 | 0.200 |
Why?
|
| Internship and Residency | 2 | 2023 | 748 | 0.190 |
Why?
|
| Frozen Sections | 1 | 2021 | 10 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 53 | 0.180 |
Why?
|
| Observer Variation | 1 | 2021 | 204 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 56 | 0.170 |
Why?
|
| Biopsy | 1 | 2021 | 375 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 157 | 0.160 |
Why?
|
| Graft Rejection | 1 | 2020 | 264 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 225 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 484 | 0.150 |
Why?
|
| Skin | 1 | 2021 | 354 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 667 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 353 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1565 | 0.130 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 27 | 0.130 |
Why?
|
| Naphthalenes | 1 | 2015 | 18 | 0.130 |
Why?
|
| Pyridones | 1 | 2015 | 35 | 0.120 |
Why?
|
| Curriculum | 2 | 2023 | 569 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 344 | 0.110 |
Why?
|
| Mentors | 1 | 2013 | 119 | 0.100 |
Why?
|
| Career Choice | 1 | 2013 | 114 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 460 | 0.100 |
Why?
|
| Male | 4 | 2023 | 27951 | 0.100 |
Why?
|
| Aged | 3 | 2023 | 13596 | 0.090 |
Why?
|
| General Surgery | 1 | 2013 | 193 | 0.090 |
Why?
|
| Students, Medical | 1 | 2013 | 246 | 0.090 |
Why?
|
| United States | 1 | 2023 | 7622 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 699 | 0.080 |
Why?
|
| Female | 3 | 2023 | 31226 | 0.060 |
Why?
|
| Animals | 1 | 2021 | 19739 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2023 | 248 | 0.050 |
Why?
|
| Middle Aged | 2 | 2020 | 16542 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2020 | 31 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 45 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 80 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 235 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2480 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 302 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3133 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 108 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2013 | 461 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5090 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2615 | 0.020 |
Why?
|